A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Patients with Spinal Muscular Atrophy (SMA) are hopeful of getting access to generic versions of Roche’s patented drug ...

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

The high court noted that SMA is a debilitating disease which has no cure, and the only approved drug, Risdiplam, marketed ...

The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...